IMO-2125, the agonist of TLR9, was revealed to lead to the production of Th1-type cytokines and chemokines.105 Treatment of IMO-2125 directly into one tumor leads to potent tumor regression of the injected and uninjected distant tumors via the CD8+ T cell directed Th1 response with a long-term tumor specific memory in the colon carcinoma mouse model.106 And phase I/II clinical trials have shown that the combination of IMO-2125 and Ipilimumab is well-tolerated and actively promotes anti-tumor immune responses in melanoma. Here, CD8A is linked to melanoma.